Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exelon Patch vs Capsules in Alzheimer's Disease
NCT01399125Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2011
- Primary completion
- May 2013
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivastigmine in Alzheimer's disease (AD) (2 arms), sponsored by Novartis. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 24 weeks. Started Jul 2011; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01399125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01399125.